Company Overview of Nascacell Technologies AG
Nascacell Technologies AG is a biotechnology company that develops products and drug development candidates based on the Microbody technology. It provides new generation of biomolecules. The company supports its customers in the areas of target validation and drug discovery through Aptamer and Microbody technologies. It serves pharmaceutical, biotechnology, and other industrial sectors. The company was founded in 2003 and is based in Munich, Germany. As of January 30, 2009, Nascacell Technologies AG is in liquidation.
3 OG Modul D
Founded in 2003
49 89 54 72 72 0
49 89 54 72 72 22
Key Executives for Nascacell Technologies AG
Nascacell Technologies AG does not have any Key Executives recorded.
Similar Private Companies By Industry
|4 Animals AlsterScience GmbH||Europe|
|Acousia Therapeutics GmbH||Europe|
|Across Barriers GmbH||Europe|
|Actinodrug Pharmaceuticals GmbH||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Nascacell Technologies AG, please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.